We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Comment & Response |

Confirmatory Testing for Onychomycosis—Reply

Anar Mikailov, MD1; Cara Joyce, PhD2; Arash Mostaghimi, MD, MPA, MPH1
[+] Author Affiliations
1Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts
2Walgreen Co, Deerfield, Illinois
JAMA Dermatol. 2016;152(7):848-849. doi:10.1001/jamadermatol.2016.0784.
Text Size: A A A
Published online


In Reply We thank Wang et al and Lipner and Scher for their interest in our study and agree with both groups about other potential consequences of terbinafine use.1 Our analysis of the adverse effects of terbinafine included only hepatic manifestations, given the US Food and Drug Administration and package insert recommendations to check transaminases prior to initiation of therapy and the availability of reliable incidence statistics from the National Library of Medicine LiverTox database. The other adverse effects mentioned by Wang et al and Lipner and Scher are certainly important; incidence statistics are not available for those adverse events, however, limiting our ability to perform a similar analysis. Nevertheless, we emphasize shared decision making with patients before prescribing systemic medications with the potential for idiosyncratic adverse drug reactions.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





July 1, 2016
Shari R. Lipner, MD, PhD; Richard K. Scher, MD
1Department of Dermatology, Weill Cornell Medicine, New York, New York
JAMA Dermatol. 2016;152(7):847. doi:10.1001/jamadermatol.2016.0785.
July 1, 2016
Apphia L. Wang, MD; Boni E. Elewski, MD; Craig A. Elmets, MD
1Department of Dermatology, University of Alabama at Birmingham School of Medicine, Birmingham
JAMA Dermatol. 2016;152(7):848. doi:10.1001/jamadermatol.2016.0786.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...